Since offering our first pediatric cancer research study over two decades ago, we have grown to serve neonates, adolescents and young adults. Clinical needs, benefits and risks are carefully weighed when choosing research studies for all populations, including children. Mary Bridge researchers work together with the Research Institute to balance standard care treatments with research interventions.
Study Number: MK-1654-002—A Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1654 in Pre-Term and Full-Term Infants
Study Number: CCD-5633AA1-02—A multi-center, double-blind, randomized, single dose, active-controlled study to investigate the efficacy and safety of Synthetic Surfactant (CHF 5633) in comparison to Porcine Surfactant (Poractant Alfa, Curosurf®) in the treatment of preterm neonates with respiratory distress syndrome.
Principal Investigator(s): Michael Kuluz, MD
Study Coordinator: Janey Barnhart, [email protected], 253-403-7258